AJP - Endo Fuel your research with LabChart
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


Am J Physiol Endocrinol Metab 295: E413-E419, 2008. First published May 27, 2008; doi:10.1152/ajpendo.00744.2007
0193-1849/08 $8.00
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
295/2/E413    most recent
00744.2007v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Google Scholar
Right arrow Articles by Rigazio, S.
Right arrow Articles by Iozzo, P.
PubMed
Right arrow PubMed Citation
Right arrow Articles by Rigazio, S.
Right arrow Articles by Iozzo, P.

The lowering of hepatic fatty acid uptake improves liver function and insulin sensitivity without affecting hepatic fat content in humans

Sara Rigazio,1 Hanna-Riikka Lehto,1 Helena Tuunanen,1 Kjell Någren,1 Mikko Kankaanpaa,1 Claudia Simi,2 Ronald Borra,1,3 Alexandru G. Naum,1 Riitta Parkkola,1,3 Juhani Knuuti,1 Pirjo Nuutila,1,4 and Patricia Iozzo1,2

1Turku Positron Emission Tomography Centre, University of Turku, Turku, Finland; 2Institute of Clinical Physiology, National Research Council, Pisa, Italy; and Departments of 3Radiology and 4Medicine, University of Turku, Turku, Finland

Submitted 27 November 2007 ; accepted in final form 21 May 2008

Lipolysis may regulate liver free fatty acid (FFA) uptake and triglyceride accumulation; both are potential causes of insulin resistance and liver damage. We evaluated whether 1) systemic FFA release is the major determinant of liver FFA uptake in fasting humans in vivo and 2) the beneficial metabolic effects of FFA lowering can be explained by a reduction in liver triglyceride content. Sixteen healthy subjects were subdivided in two groups of similar characteristics to undergo positron emission tomography with [11C]acetate and [11C]palmitate to quantify liver FFA metabolism (n = 8), or magnetic resonance spectroscopy (MRS) to measure hepatic fat content (n = 8), before and after the acute lowering of circulating FFAs by using the antilipolytic agent acipimox. MRS was again repeated after a 1-wk treatment period. Acipimox suppressed FFA levels while stimulating hepatic fractional extraction of FFAs (P < 0.05). As a result, fasting liver FFA uptake was decreased by 79% (P = 0.0002) in tight association with lipolysis (r = 0.996, P < 0.0001). The 1-wk treatment induced a significant improvement in systemic (+30%) and liver (+70%) insulin sensitivity (P < 0.05) and decreased circulating triglycerides (–20%, P = 0.06) and liver enzymes (ALT –20%, P = 0.03). No change in liver fat content was observed after either acute or sustained FFA suppression. We conclude that acute and sustained inhibitions of lipolysis and liver FFA uptake fail to deplete liver fat in healthy human subjects. Liver FFA uptake was decreased in proportion to FFA delivery. As a consequence, liver and systemic insulin sensitivity were improved, together with liver function, independently of changes in hepatic triglyceride accumulation.

lipolysis; liver metabolism; positron emission tomography; magnetic resonance; acipimox; insulin resistance



Address for reprint requests and other correspondence: P. Iozzo, Turku PET Centre, Univ. of Turku, P. O. Box 52, FIN-20521 Turku, Finland (e-mail: patricia.iozzo{at}ifc.cnr.it)







HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Visit Other APS Journals Online
Copyright © 2008 by the American Physiological Society.